The latest progress in the adjustment of the medical insurance drug list in 2022: 344 drugs passed the preliminary form review

On September 6, the National Medical Security Bureau announced the list of drugs that passed the preliminary form review in the adjustment of the national basic medical insurance, work injury insurance and maternity insurance drug catalogue in 2022, and 344 drugs passed the preliminary form review
.
The adjustment of the national medical insurance information platform received a
total of 537 enterprise declarations, involving 490 drugs (generic names, the same below).
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.

Compared with 2021 (271 of the 474 drugs passed), the number of drugs declared and passed the preliminary form examination has increased
to a certain extent.
In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.

What is preliminary formality examination? The preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug list in that year and the completeness of drug information.
The preliminary formal review of the drug declaration materials can ensure that the declared drugs meet the declaration conditions on the one hand, and on the other hand, the completeness and standardization of the declaration materials are reviewed, and the authenticity of some information is verified to the relevant parties according to the needs of the work, which is conducive to ensuring that the information provided to the experts is more accurate and complete
.
At the same time, in order to actively accept social supervision, to ensure that the results of the formal examination are accurate
.
According to the "Interim Measures for the Administration of Drugs in Basic Medical Insurance" and the "2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue Adjustment Work Plan" (hereinafter referred to as the "Work Plan"), the adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding, and other links, and the formal review is only one
of them.
Passing the formal examination indicates that the drug is eligible for the next step of expert review
.
Some new crown pneumonia treatment drugs have passed preliminary formal review In the context of the normalization of epidemic prevention and control, since the first implementation of the self-declaration system of medical insurance drug catalogue enterprises in 2020, the National Medical Insurance Bureau has attached great importance to the treatment of new crown pneumonia drugs, and has taken "drugs included in the "diagnosis and treatment plan for new coronavirus pneumonia" (hereinafter referred to as the "diagnosis and treatment plan") as one
of the declaration conditions.
A number of new crown treatment drugs have been included in the medical insurance drug list
.
This year, the ninth edition of the "Diagnosis and Treatment Plan" included a number of drugs
that had just been listed in China.
In the process of this declaration, some drugs have made self-declarations and passed the preliminary formal review, and some drugs have not been declared, in this regard, the National Medical Insurance Bureau expressed respect for the choice of
enterprises.
For drugs that have been declared and passed the formal examination, the National Medical Insurance Bureau will carry out follow-up work in accordance with the procedures and strive to be formally included in the medical insurance directory
at a reasonable price.
The medical insurance drug list has been adjusted for 4 consecutive years, and 507 new drugs and good drugs have been included in the cumulative inclusion of 507 new drugs since its establishment in 2018, and the national medical insurance bureau has always attached great importance to the management of the medical insurance drug list, and the access method of the medical insurance drug list has been majorly reformed
.
Through the establishment of a dynamic adjustment mechanism for the medical insurance drug list, the adjustment cycle has been greatly reduced from the longest eight years in the past to one year, with a total of 507 new drugs and good drugs in 4 years, 391 drugs with uncertain efficacy, and the current version of the medical insurance list of Western medicines and proprietary Chinese medicines increased to 2860.

The shortcomings of oncology drugs, chronic diseases, rare diseases and children's drugs have been gradually filled, the structure and efficacy level of drugs in the medical insurance catalogue have been greatly optimized, and the drug guarantee in most treatment areas has been synchronized with the international community, and the protection capacity has been significantly improved
.
Among them, 250 drugs have been included in medical insurance through price negotiations, many "sky-high drugs" have negotiated "civilian prices", and most drugs have obtained the lowest prices in the world, with an average price reduction of more than 50%.

(CCTV reporter Zhang Ping Yizhe) Enterprise What is preliminary form review? Some new crown pneumonia treatment drugs have passed preliminary formal review The medical insurance drug list has been adjusted for 4 consecutive years and has included 507 new drugs and good drugs for children with tumors